Gavin Gassen, MD
Otolaryngology · Poughkeepsie, NYNPI 1508836636
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,943 of the $4,551 with a category attached, or 64.7%. Smith+Nephew accounts for 75.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $3,913 and has fallen 97.8% since, to $86 in 2025.
Across 24 payments — averaging $189.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$3K
- Medtronic$406
- Stryker$188
- Aerin Medical Inc.$171
- Intersect ENT, Inc.$152
- Optinose US, Inc.$108
- plus $114 from 5 others
What the payments were for
- Travel & lodging$2,94365%
- Food & beverage$1,60835%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 7 | $3,412 |
| Medtronic | 3 | $406 |
| Stryker | 4 | $188 |
| Aerin Medical Inc. | 1 | $171 |
| Intersect ENT, Inc. | 2 | $152 |
| Optinose US, Inc. | 1 | $108 |
| Inspire Medical Systems, Inc. | 2 | $49 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Coblation$2,382
- TULA$2,382
- TRIGEN$1,004
- PROPEL$190
- VIVAER STYLUS$171
- RHINAER STYLUS$171
- Xhance$108
How this compares
$4,551 in reported general payments places this provider in the 80th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 16 | $1,260 |
| Gabapentin | 11 | $922 |
| Ipratropium Bromide | 24 | $905 |
| Fluticasone Propionate | 42 | $881 |
| Mometasone Furoate | 15 | $875 |
| Azelastine Hcl | 12 | $409 |
| Omeprazole | 20 | $398 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Poughkeepsie
- Robert KellmanSyracuse$2.5M
- Roheen RaithathaNew York$830K
- Nora PerkinsAlbany$300K
- Moshe EphratNew Hyde Park$250K
- Gavin SetzenAlbany$243K
- Habibullah JamalRye Brook$179K
- Albert JenFlushing$171K
- Dennis KrausNew York$159K
- Nitin BhatiaWhite Plains$120K
- Sveta KarelskyRochester$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.